Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number Filing Date First Named Inventor Akitor Art Unit Examiner Name C. Kir			10743457		
			2003-12-23 itoshi NAKAJIMA 3682		
		Akito			
		C. Ki	im		
Attorney Docket Number		er	90606.3		

		·		U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6312159		2001-11-06	Ishida et al.	
	2	3576353		1971-04-27	Barker et al.	
	3	4693139		1987-09-15	Mukai et al.	
	4	6125536		2000-10-03	Spumy	
	5	5208979		1993-05-11	Schmidt	
If you wis	h to a	dd additional U.S. Paten		-	ease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					
If you wisi	h to a	i dd additional U.S. Publis	hed Ap	plication citation	I n information please click the Ad-	d button. Add
				FOREIGN PAT	TENT DOCUMENTS	Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10743457	
Filing Date		2003-12-23	
First Named Inventor	Akitoshi NAKAJIMA		
Art Unit		3682	
Examiner Name	C. Kim		
Attorney Docket Number		90606.3	

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	where Relevant Passages or Relevant Figures Appear	Ts
	1	3618742	DE	A1	1987-12-10			✓
If you wis	h to a	dd additional Foreign	Patent Documer	nt citation	information p	lease click the Add butto	n Add	
			NON-PAT	ENT LITE	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	xaminer citie include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					Τs		
Official Communication issued in the corresponding European Application Number 03 2006.					plication Number 0302994	1.6, dated March 31,		
If you wis	h to a	dd additional non-pate	nt literature doc	ument ci	tation informat	ion please click the Add	button Add	_
			E	XAMINE	R SIGNATUR	E		
Examiner	Signa	ture				Date Considered		
*EXAMIN	ER: Ir	itial if reference consi	dered, whether	or not cit	ation is in conf	ormance with MPEP 609	B. Draw line through a	

E

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language translation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10743457		
Filing Date		2003-12-23		
First Named Inventor Akitor		shi NAKAJIMA		
Art Unit		3682		
Examiner Name	C. Kim			
Attorney Docket Number		90606.3		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 at	d 1.98 to make the	appropriate selection(s):
---------------	-------------	--------------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information sidelosure statement. See 37 CFR 197(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
 - □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Joseph R. Keating #37,368/	Date (YYYY-MM-DD)	2006-06-14
Name/Print	Incenh P. Kastino	Registration Number	3736R

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to a patient application or patient. If you do not furnish the requested the process another examine your submission, which may visually intermediate or of redesting to a submission or the basic log process another examine; your submission, which may visually intermediate or of redesting to a submission or the submission or the submission of the submission or the submission of the submission of the submission or the submission of the submission or the submission of the submission or the submission or the submission of the submission or the submission or the submission or the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.